Aptarro Appoints Emily Williams as Chief Financial Officer to Support Continued Growth, Scalability, and Value Creation

Aptarro Appoints Emily Williams as Chief Financial Officer to Support Continued Growth, Scalability, and Value Creation

Aptarro, a leading provider of revenue cycle technology for healthcare organizations, announces Emily Williams as Chief Financial Officer. With extensive experience leading finance in high-growth, private equity-backed software companies, Williams will play a key role in driving Aptarro’s continued growth, operational scale,…

Read MoreAptarro Appoints Emily Williams as Chief Financial Officer to Support Continued Growth, Scalability, and Value Creation
EDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development

EDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development

EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advancements in digital transformation within the life sciences industry. This engagement combines EDETEK’s deep domain expertise and established platforms and services with…

Read MoreEDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

–Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) (“Evofem”), to Aditxt’s Board of Directors. “We believe that Saundra’s background as a…

Read MoreEvofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors
ESMO Open Study Shows Guardant Reveal Effective in Early Breast Cancer MRD Detection

ESMO Open Study Shows Guardant Reveal Effective in Early Breast Cancer MRD Detection

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced results from the LIBERATE study published in ESMO Open.The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company’s minimal residual disease (MRD)…

Read MoreESMO Open Study Shows Guardant Reveal Effective in Early Breast Cancer MRD Detection
Fable Therapeutics Appoints David J. Baker, PhD, as Chief Scientific Officer

Fable Therapeutics Appoints David J. Baker, PhD, as Chief Scientific Officer

Fable Therapeutics, a discovery-stage biotechnology company developing purpose-built biologics powered by state-of-the-art structure and sequence-based protein language models, today announced the appointment of David J. Baker, PhD, as Chief Scientific Officer (CSO). “David’s extensive experience in drug discovery, with a…

Read MoreFable Therapeutics Appoints David J. Baker, PhD, as Chief Scientific Officer
Butterfly Network’s RoHS Exemption Request Moves to Stakeholder Review

Butterfly Network’s RoHS Exemption Request Moves to Stakeholder Review

Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced that the European Commission has officially initiated the review and stakeholder consultation period for the Company’s request to revoke Annex IV n.…

Read MoreButterfly Network’s RoHS Exemption Request Moves to Stakeholder Review
HistoSonics Completes Enrollment in HOPE4KIDNEY Trial for Non-Invasive Tumor Treatment

HistoSonics Completes Enrollment in HOPE4KIDNEY Trial for Non-Invasive Tumor Treatment

HistoSonics Completes Enrollment in HOPE4KIDNEY Trial for Non-Invasive Tumor Treatment HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm…

Read MoreHistoSonics Completes Enrollment in HOPE4KIDNEY Trial for Non-Invasive Tumor Treatment
OS Therapies Seeks RMAT Status from FDA for OST-HER2 in Pediatric Osteosarcoma

OS Therapies Seeks RMAT Status from FDA for OST-HER2 in Pediatric Osteosarcoma

OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the…

Read MoreOS Therapies Seeks RMAT Status from FDA for OST-HER2 in Pediatric Osteosarcoma
Aethera Biotech Partners with Shang Renée to Bring CROP Tech to China

Aethera Biotech Partners with Shang Renée to Bring CROP Tech to China

Aethera Biotech officially announced a strategic partnership with Chinese premium skincare brand Shang Renée, marking the latter as Aethera Biotech’s first collaborative partner in the Chinese market. This collaboration not only introduces the internationally pioneering CROP patent technology to China…

Read MoreAethera Biotech Partners with Shang Renée to Bring CROP Tech to China